The most common (incidence >2.0% of patients) TEAEs leading to discontinuation of pamiparib were in the “hepatobiliary disorders” and “investigations” MedDRA system organ classes (4.4% and 2.8% of patients, respectively), and included hepatitis (2.2%) and ALT increased (2.2%). This evidence concerns the gene GPT and hepatobiliary disorder.